| Status: One Wales interim decision | ||
Arsenic trioxide in combination with all-trans retinoic acid can be made available within NHS Wales for the first line treatment of high-risk acute promyelocytic leukaemia, characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha gene, in adult patients unsuitable for anthracycline-based therapy. The risks and benefits of the off-label use of arsenic trioxide for this indication should be clearly stated and discussed with the patient to allow informed consent. In November 2016 OWMAG recommended this treatment in NHS Wales, in September 2023 there was a review of the recommendation. OWMAG found nothing new that effects the original decision. Next review: this decision will be reviewed again after three years or earlier if new evidence becomes available. |
||
|
||
Medicine details |
||
| Medicine name | arsenic trioxide | |
| Formulation | Concentrate for solution for infusion | |
| Reference number | OW06 | |
| Indication | In combination with all-trans retinoic acid for the first-line treatment of high-risk acute promyelocytic leukaemia in adult patients unsuitable for anthracycline-based therapy |
|
| Company | Various | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | One Wales | |
| Status | One Wales interim decision | |
| Date of issue | 01/11/2016 | |
| Date of last review | September 2023 | |